Retina DiseaseNCT07796230
Modified P200TE Data Collection
An observational study of Retina Disease, run by Optos, PLC at 1 site in United States.
Trial summary
Images will be collected on the modified P200TE Read more about this study
- Who is it for?
- Ages 22 years and olderHealthy volunteers can take part
- Conditions the study is for
- Retina Disease
- What is being tested?
- imaging device
- Type of treatment
- Medical device
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 29 Jul 2026to 1 Oct 2026
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants with eye disease seen at a US clinical site
Who may be able to join
- Male or female participants 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed
- Participants who can follow the instructions by the clinical staff at the clinical site
- Participants who agree to participate in the study
- Participants with posterior segment eye disease. Example of pathologies may include but are not limited to Age-related macular degeneration, glaucoma, diabetic retinopathy, posterior uveitis, central serous chorioretinopathy, vein occlusion, epiretinal membrane and others as confirmed by the investigator.
Who cannot join
- Participants unable to tolerate ophthalmic imaging.
- Participants with ocular media not sufficiently clear to obtain acceptable images.
- Unable to obtain acceptable image quality on participant.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Bennett & Bloom Eye Centers
Louisville, Kentucky, 40222
Megan Kingdon, (502) 895-0040, megankingdon@eyecarepartners.com
About this study
Images will be collected on the modified P200TE
- Conditions
- Retina Disease
- Being tested
- imaging device
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
imaging deviceDevice
images captured on a modified P200TE
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of images
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2026
- Study start29 Jul 2026
- Primary completion1 Oct 2026 (estimated)
- Study completion1 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Retina DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Optos, PLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07796230
- Sponsor's protocol ID
- OPT1123
- Status last verified
- Aug 2026
- First submitted
- 27 Aug 2026
- Last updated
- 1 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Modified P200TE Data Collection
- ClinicalTrials.gov ID
- NCT07796230
- Acronym / sponsor ID
- OPT1123
- Conditions
- Retina Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Optos, PLCIndustry (pharma, biotech, devices)
- Study start
- 29 Jul 2026 (actual)
- Primary completion
- 1 Oct 2026 (estimated)
- Study completion
- 1 Oct 2026 (estimated)
- First posted
- 1 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Images will be collected on the modified P200TE
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants with eye disease seen at a US clinical site
Key inclusion criteria (4 listed)
- Male or female participants 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed
- Participants who can follow the instructions by the clinical staff at the clinical site
- Participants who agree to participate in the study
- Participants with posterior segment eye disease. Example of pathologies may include but are not limited to Age-related macular degeneration, glaucoma, diabetic retinopathy, posterior uveitis, central serous chorioretinopathy, vein occlusion, epiretinal membrane and others as confirmed by the investigator.
Key exclusion criteria (3 listed)
- Participants unable to tolerate ophthalmic imaging.
- Participants with ocular media not sufficiently clear to obtain acceptable images.
- Unable to obtain acceptable image quality on participant.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| imaging deviceimages captured on a modified P200TE | Device | – |
Primary outcome
Number of images
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Retina Disease
RecruitingObservational study
Adaptive Optics Retinal Imaging
Eye Diseases, Healthy Volunteers
RecruitingObservational study
National Eye Institute Biorepository for Retinal Diseases
Age-Related Macular Degeneration, Diabetic Retinopathy
Active, not recruitingObservational study
Natural History of Eye Diseases Related to ABCA4 Mutations
Retinal Degeneration, ABCA4-Related Retinopathies
Active, not recruitingPhase 3
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Macular Neovascularization Secondary to Age-Related Macular Degeneration
RecruitingObservational study
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
Diabetes Complications, Diabetic Retinopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Retina Disease, run by Optos, PLC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of images (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.